TRACK CHANGES FOR ABSTRACT SUBMITTERS

This table outlines the updated track structure for the **2026 Global Annual Meeting**, highlighting the new track titles, order, and key changes to help abstract submitters align their proposals effectively.

KEY NOTES FOR ABSTRACT SUBMITTERS:

- Patient engagement is now **woven throughout all tracks** rather than isolated.
- Project Management content is **merged into Track 6** to strengthen focus on leadership and strategic execution.
- RWE has been **split across Tracks 3 (data capture/enablement) and 10 (methodology/analysis)** for clearer submission pathways.
- Regulatory content has been **expanded and clarified**, now separated into two strong tracks: Regulatory CMC & Product Quality (Track 7) and Regulatory Policy, Strategy & Global Collaboration (Track 8).

Abstract submitters should review these updated tracks carefully and select the one that best matches their topic under this revised structure.

PREVIOUS TRACK *(2025)*	NEW TRACK *(2026)*	KEY CHANGES
1. Clinical Safety & Pharmacovigilance	**1.** Clinical Safety, Pharmacovigilance and Risk Management	Expanded scope to explicitly include risk management as a core deliverable of pharmacovigilance, aligning with DIA's specialty meetings.
2. Clinical Trials & Clinical Operations	**2.** Clinical Trial Operations and Innovation	Refined to emphasize operational excellence, project management, technology-enabled execution, inclusive trials, and site/patient engagement.
3. Data & Technology	**3.** Data, Technology and AI	Expanded focus on AI/ML, real-world evidence (RWE), data integration, policy-driven data innovation, and decentralized trial solutions.
4. Medical Affairs and Scientific Communications	**4.** Medical Affairs and Scientific Communication	Updated to highlight evolving regulatory engagement, scientific messaging, technology adoption in medical writing, and expanded project management leadership elements.
5. Patient Impact on Product Development	*Removed as standalone track*	Patient perspectives are now integrated across all tracks, with emphasis on inclusive trial design, patient voice in safety/risk management, and patient-focused regulatory decision-making.
6. Personalized Medicine, Combination Products & Diagnostics	**5.** Personalized Medicine, Combination Products and Diagnostics	Updated description to emphasize convergence of medicines, diagnostics, and devices, translational medicine advances, and integration of patient voice early in development.
7. Project Management & Strategic Planning	**6.** Professional Development and Project, Program and Portfolio Management	Merged with Professional Development track to streamline content, highlight project management fundamentals, strategic execution, and leadership skills as core professional growth areas.
8. R&D Quality & Compliance	**9.** R&D Quality and Compliance	Retained focus on risk-based quality management, culture of quality, GCP compliance, AI/ML-enabled oversight, and successful data governance strategies.
9. Regulatory	**8.** Regulatory Policy, Strategy and Global Collaboration	Expanded to include global convergence, health authority modernization, benefit-risk decision-making, patient-focused drug development, and advanced modalities under one strategic regulatory track.
10. Regulatory CMC & Product Quality	**7.** Regulatory CMC and Product Quality	Retained scope, enhanced emphasis on global convergence, CMC dossier innovation, supply chain resilience, and strategies for accelerated pathways.
11. Statistics & Data Science	**10.** Statistics, Evidence Generation and Real-World Data	Added explicit focus on RWE methodologies, HTA, innovative trial designs, benefit-risk analytics, and the evolving role of biostatistics, data science, and AI in regulatory decision-making.
12. Professional Development	**6.** Professional Development and Project, Program and Portfolio Management	Merged with Project Management track as described above to reduce overlap and ensure project management expertise is retained and elevated.